Skip to content
Screener

Polaryx Therapeutics, Inc. PLYX Q1 2026 earnings

Reported May 15, 2026 · Before market open

EPS-$0.05Miss by $0.03
EPS estimate-$0.02

Next report

Date not yet announced

Financials

Q1 2026

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M—

Cash flow

See full
Operating cash flow-$2.1M-191%

Versus estimates

Diluted EPS

Q2 2026-$0.03Beat by $0.01
Q1 2026-$0.05Miss by $0.03
Q4 2025-$0.13Miss by $0.11Q3 2025-$0.03

FAQ

When did Polaryx Therapeutics, Inc. report Q1 2026 earnings?
Polaryx Therapeutics, Inc. (PLYX) reported Q1 2026 earnings on May 15, 2026 before market open.
What were Polaryx Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Polaryx Therapeutics, Inc. reported eps of $-0.05 for Q1 2026.
Did Polaryx Therapeutics, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.02 by $0.03.
Where can I find Polaryx Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 10-Q periodic report (0001213900-26-056973) directly on SEC EDGAR. The filing index links above go to sec.gov.